PTC Therapeutics officer sells shares under 10b5-1 plan

PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse.

Rhea-AI Filing Summary

PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse. On March 5, 2026, his spouse sold 3,989 shares of common stock at $63.38 per share in a sale classified as an open-market or private transaction.

This transaction was carried out under a written Rule 10b5-1 trading plan adopted by Almstead on November 26, 2025. Following the sale, his spouse held 2,737 shares of common stock indirectly, while Almstead held an additional 112,140 shares of common stock directly.

Insider Trade Summary

Net Seller: 3,989 shares

Net Sell 2 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 3,989 shs ($253K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,989	$63.38	$253K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,737 shares (Indirect, By Spouse); Common Stock — 112,140 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 26, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTCT executive Neil Gregory Almstead report?

Neil Gregory Almstead reported his spouse’s sale of 3,989 shares of PTC Therapeutics common stock. The shares were sold on March 5, 2026, in an open-market or private transaction at $63.38 per share, under a pre-arranged Rule 10b5-1 trading plan.

At what price were the PTCT shares sold in the reported insider trade?

The reported insider trade involved selling PTC Therapeutics common stock at $63.38 per share. This price applied to 3,989 shares sold on March 5, 2026, in an open-market or private transaction executed under a written Rule 10b5-1 trading plan.

How many PTCT shares did Neil Gregory Almstead’s spouse hold after the sale?

After the sale, Neil Gregory Almstead’s spouse held 2,737 shares of PTC Therapeutics common stock indirectly. These shares are reported as indirect ownership, while Almstead separately held 112,140 shares of common stock directly in his own name following the reported transaction.

How many PTCT shares does Neil Gregory Almstead hold directly after this Form 4 filing?

Following the reported transaction, Neil Gregory Almstead directly held 112,140 shares of PTC Therapeutics common stock. This direct ownership is separate from the 2,737 shares held indirectly by his spouse, which are reported as indirect beneficial ownership on the Form 4.

Was the PTCT insider sale by Neil Gregory Almstead’s spouse under a Rule 10b5-1 plan?

Yes. The sale of 3,989 PTC Therapeutics shares by Neil Gregory Almstead’s spouse was executed under a written Rule 10b5-1 trading plan. The plan was adopted by Almstead on November 26, 2025, before the March 5, 2026 sale date disclosed in the filing.

What type of transaction was reported in Neil Gregory Almstead’s PTCT Form 4?

The Form 4 reports an open-market sale of PTC Therapeutics common stock, coded as a “S” transaction. It involved 3,989 shares sold at $63.38 per share on March 5, 2026, and is described as a sale in an open market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								112,140	D
Common Stock	03/05/2026		S(1)		3,989	D	$63.38	2,737	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 26, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.